- May 21, 2015- Agenda for KEI/KEI Europe panel on Compulsory licensing of patents on drugs, vaccines and diagnostic tests
- WHA68: Greek Minister of Health - Panagiotis Kouroumplis - calls for de-linkage of R&D from the price of health technologies
- KEI TPP Briefing note 2015:1 Compulsory licenses on patents and the 3-step test
- Letter from Senator Bernie Sanders to the VA, asking for compulsory licenses on Hepatitis C drugs.
- UACT Comments to DHHS on WHA: Agenda Item 13.4 Assessment of Progress in Prevention & Control of NCDs
- KEI Comments to DHHS on WHA Agenda 17.5 (Global Strategy and Plan of Action on Public Health, Innovation and IP)
- KEI comments to DHHS on WHA agenda 17.4, the Consultative Expert Working Group on Research and Development
- KEI Comments on DHHS Session on WHA68, agenda item 14.1, regarding collection of economic data
- KEI Comments to DHHS on WHA68 agenda 11.2, Framework of Engagement with Non-State Actors
- WHO Expert Committtee adds trastuzumab, imatinib, daclatasvir, sofosbuvir, bedaquiline and delaminid to EML
Following Professor Crews' presentation of his updated report on limitations and exceptions (L&E) for libraries and archives, today more member states, IGOs and NGOs engaged again in an interesting Q&A. After years in this committee, I have rarely witnessed such enthusiasm and interest among all the SCCR participants about a report.
The SCCR 29 went again into informals this morning and NGOs can listen but not report on what is going on. As per the agenda, the broadcasting treaty is still the topic of discussion. While the US delegation was supporting making the charts describing the definitions, concepts and rights being discussed available to the public, there were other delegations (TBD) against it and the charts are thus still "secret".
We are reconvening into plenary after the coffee break.
Also presented during the afternoon plenary, here are 3 statements by public interest organizations, the TACD, EFF and CIS:
SCCR29 At 3pm, the plenary reconvened and the NGOs made their statements regarding the rights, definitions and concepts of the proposed broadcasting treaty discussed during the informal with the help of charts.
On the public interest side we only had KEI, TACD, EFF and CIS. I will post these statements in another blog. Here are 3 statements that are good examples of what the arguments were for the broadcasters (the European Broadcasting Union) followed by the push back by the IFFPI (representing the music industry) and finally the FIAP (film industry also pushing back).
Below is a cleaned up version of the transcript, from my rambling intervention for KEI on the broadcasting treaty definitions.
Thank you, Mr. Chairman. My comments would be initially on the definitions.
It is our position that it's more appropriate to provide protection for free services that are traditionally provided by radio and television and less appropriate for pay services,
To understand the negotiations this week at the WIPO SCCR 29, it is helpful to review an April 2014 document, endorsed by several broadcasting organizations.
The attached document* is a joint statement by 12 broadcasting organizations, on "THE OBJECTIVES, SPECIFIC SCOPE AND OBJECT OF THE PROPOSED WIPO BROADCASTERS' TREATY".
The December 9, 2014 SCCR morning session started with the Chair's summary of yesterday informals. The delegates discussed 3 charts. The first chart called "a technological platforms chart" is supposed to clarify the scope of protection of the new instrument, the broadcasters' treaty. The second chart is called "a rights chart". And additionally, the Chair prepared a third chart which was called a definitions chart, which contained the definitions of broadcasting organization, broadcasting transmission and signal.
The morning session of SCCR 29 (Dec 8-12, 2014) ended with a coffee break which will be followed by informals (that we are not allowed to report on at this point). After the usual decisions this morning i.e, Adoption of the agenda of the twenty ninth session then Accreditation of new non governmental organizations (and yes, the Program on Information Justice and Intellectual Property (PIJIP) is in!) we had the Adoption of the Report of the Twenty-Eighth Session of the Standing Committee on Copyright and Related Rights.
The World Intellectual Property Organization's 29th Standing Committee on Copyright and Related Rights (SCCR) is meeting in Geneva from 8-12 December 2014. WIPO has a live stream of the proceedings; the password is sccr29. The opening statement of the European Union is contained below.
The attached PDF file provides counts on the number of patents with various search terms in the specification (spec/"search term"), and the number of those patents that declare either government rights in the patents (govt/government), an assignment to the US government (an/"united states of america"), or both. The complete counts are in the PDF file. The queries were done by Claire Cassedy on December 5, 2014.
On Wednesday, 10 December 2014, Knowledge Ecology International (KEI) will convene a side event entitled, "The Broadcasting Treaty: A Solution in Search of a Problem?"; the event will take place in Room B of the World Intellectual Property Organization (WIPO) from 13:30 to 15:00.
The NIH has a notice about a proposed rule that "clarifies and expands requirements for the submission of clinical trial registration and results information to the ClinicalTrials.gov database." Comments are due on or before February 19, 2015. We may ask the NIH to consider expanding the trials registry to include more information on the economics of clinical trials.
Here is a link to the Regulations.Gov docket for the proposed rule:
On November 24, 2014. the Union for Affordable Cancer Treatment (UACT) sent a letter to Anthony P. Monaco, Office of the President, Tufts University, with copies to Michael Baenen, the Tufts Chief of Staff, and Peter Dolan, Chairman of the Board of Trustees for Tufts University, regarding the Tufts University press conference to announce an estimate of $2.6 billion as the R&D costs for new drugs.
Leading up to the release of Professor Joe DiMasi's latest study of the cost of drug development, KEI offered $50 to the individual who could most accurately predict the new cost for drug R&D.
We received 26 guesses, ranging from $1.157 billion to $5 billion.
Joel Lexchin's estimate ($2.47 billion) was the closest to DiMasi's number ($2.558 billion). It was also the 5th largest estimate.
A complete list of submissions is below.
Name & Guess
Charles Clift - 1.157 billion
Nicole H - 1.2 billion
Ronald Rader - 1.55 billion
Wouter Deelder - 1.655 billion